QUOIN PHARMACEUTICALS ($QNRX) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of -$1.77 per share, beating estimates of -$1.97 by $0.20. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $QNRX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
QUOIN PHARMACEUTICALS Hedge Fund Activity
We have seen 14 institutional investors add shares of QUOIN PHARMACEUTICALS stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- IKARIAN CAPITAL, LLC added 211,538 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,052,493
- WOODLINE PARTNERS LP added 79,582 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,148,368
- STONEPINE CAPITAL MANAGEMENT, LLC added 78,189 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,128,267
- MILLENNIUM MANAGEMENT LLC added 74,817 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,079,609
- SUMMITTX CAPITAL, L.P. added 64,795 shares (+inf%) to their portfolio in Q4 2025, for an estimated $934,991
- BOOTHBAY FUND MANAGEMENT, LLC added 59,838 shares (+inf%) to their portfolio in Q4 2025, for an estimated $863,462
- ADAR1 CAPITAL MANAGEMENT, LLC added 58,230 shares (+inf%) to their portfolio in Q4 2025, for an estimated $840,258
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
